US IP Litigation Risk for Listed Companies: Defence Strategies Against Patent Trolls

The decision by the United States Patent and Trademark Office (USPTO) in June 2025 to finalise rules tightening inter partes review (IPR) procedures, combined with the Eastern District of Texas’s continued dominance in patent litigation filings, has materially altered the risk calculus for Hong Kong and PRC companies listed on the NYSE or Nasdaq. According to the 2025 Patent Litigation Report published by Unified Patents, the number of new patent cases filed by Non-Practicing Entities (NPEs) — commonly known as patent trolls — against publicly traded companies increased by 18.7% year-over-year, with technology and life sciences issuers on US exchanges absorbing 62% of all NPE assertions. For a Hong Kong-headquartered company that has completed a US IPO via a traditional firm commitment underwriting or a de-SPAC transaction, the exposure is structural: the US discovery regime under the Federal Rules of Civil Procedure permits broad, extraterritorial document requests, and a single adverse jury verdict in a venue like the Western District of Texas can impose damages exceeding the company’s entire annual R&D budget. This article provides a data-driven framework for CFOs and company secretaries of US-listed Hong Kong issuers to evaluate IP litigation risk, deploy pre-emptive defensive mechanisms, and structure a cost-effective response strategy that aligns with both US federal procedure and Hong Kong’s own legal obligations under the Patents Ordinance (Cap. 514).

The Structural Exposure of US-Listed Hong Kong Issuers to NPE Litigation

The jurisdictional reach of US patent law creates a unique vulnerability for Hong Kong companies that have raised capital on a US exchange. A listing on the NYSE or Nasdaq, by definition, places the issuer’s equity securities in the hands of US residents, and the US courts have consistently held that this alone can establish personal jurisdiction under the “stream of commerce” theory articulated in Daimler AG v. Bauman (2014) and refined in Ford Motor Co. v. Montana Eighth Judicial District Court (2021). The practical consequence is that a Hong Kong company with no physical presence in the United States, no US sales office, and no US manufacturing facility can still be haled into a US district court to defend a patent infringement claim.

The NPE Targeting Pattern: Post-IPO Vulnerability Windows

Empirical data from the 2024 RPX Annual Patent Litigation Report shows that 41% of NPE lawsuits against companies that went public on US exchanges in the preceding 36 months were filed within the first 18 months post-IPO. This window corresponds to the period when the issuer’s prospectus — filed with the SEC on Form F-1 for foreign private issuers — has publicly disclosed the company’s core technology, product roadmap, and key revenue-generating patents. NPEs systematically mine these public filings to identify potential infringement targets. For a Hong Kong issuer that used a Cayman Islands or Bermuda holding company structure, the NPE’s complaint will typically name the Cayman parent, the Hong Kong operating subsidiary, and any US-based sales or marketing subsidiaries as co-defendants, thereby subjecting all entities to the same discovery obligations.

The Financial Impact: Defence Costs and Damages Benchmarks

The American Intellectual Property Law Association (AIPLA) 2024 Report of the Economic Survey provides the most authoritative cost benchmarks: median litigation costs through trial for a patent case with USD 10 million to USD 25 million at risk are USD 3.5 million, and for cases with over USD 25 million at risk, the median rises to USD 6.0 million. These figures exclude the cost of any damages award or settlement. In the Eastern District of Texas, the median jury award in patent cases decided in 2024 was USD 18.7 million, according to data compiled by Docket Navigator. For a Hong Kong company with a market capitalisation of HKD 5 billion to HKD 20 billion, a single adverse verdict at that level can represent 3% to 12% of market cap, triggering a share price decline that compounds the direct financial loss.

Pre-Listing Defensive Structuring: Patent Portfolio Audits and Covenant Design

The most cost-effective defence against NPE litigation begins before the F-1 is filed with the SEC. Hong Kong issuers undertaking a US IPO should integrate patent risk assessment into the due diligence workstream managed by the sponsor — the equivalent of the Hong Kong sponsor regime under the SFC’s Code of Conduct for Persons Licensed by or Registered with the SFC, though the US framework has no direct analogue to the sponsor’s statutory liability under the Hong Kong Listing Rules.

Patent Landscape Clearance and Invalidity Searches

A pre-IPO patent landscape clearance, conducted by a US-licensed patent attorney or a qualified patent agent, serves two functions. First, it identifies any third-party patents that read on the issuer’s core technology, allowing the company to assess the probability of an infringement assertion. Second, it identifies prior art that can be used to invalidate those patents through IPR proceedings at the USPTO. The cost of a comprehensive landscape clearance for a company with 20 to 50 patent families is typically USD 75,000 to USD 150,000 — a fraction of the cost of a single year of litigation. The Hong Kong Patents Ordinance (Cap. 514) permits standard patents based on a corresponding application filed at the USPTO, the UK Intellectual Property Office, or the European Patent Office; a pre-IPO clearance should therefore also review the validity of the issuer’s own Hong Kong standard patents, as NPEs may assert these in Hong Kong courts under the ordinance’s infringement provisions.

Forum Selection and Indemnification Clauses in Underwriting Agreements

The underwriting agreement for a US IPO — typically governed by New York law — can include a forum selection clause that designates the Southern District of New York as the exclusive venue for any patent infringement claims arising from the offering. While such clauses are not dispositive against NPEs that are not parties to the agreement, they can be used to argue that the NPE’s choice of a plaintiff-friendly venue like the Eastern District of Texas is improper. The Hong Kong issuer should also negotiate indemnification provisions with its US underwriters that cover patent-related liabilities, though the underwriters will typically cap this exposure at the underwriting discount (usually 5.5% to 7.0% of gross proceeds for a traditional IPO on the Nasdaq).

Post-Listing Defence Tactics: IPR Petitions, Early Motions, and Settlement Architecture

Once a complaint is filed, the issuer must move rapidly to control costs and limit exposure. The USPTO’s IPR process, established under the America Invents Act of 2011, remains the most effective tool for invalidating weak patents asserted by NPEs. The 2025 rule changes increased the threshold for instituting an IPR, requiring the petitioner to show a “reasonable likelihood” that at least one challenged claim is unpatentable — a standard that the USPTO’s Patent Trial and Appeal Board (PTAB) has applied more strictly since the Fintiv factors were codified in 2024.

The IPR Strategy: Timing and Cost-Benefit Analysis

An IPR petition must be filed within one year of service of the complaint. The PTAB’s decision on institution typically issues within six months, and a final written decision within 12 to 18 months of institution. The cost of a fully briefed IPR with expert declarations is USD 300,000 to USD 500,000, according to the AIPLA survey. If the PTAB invalidates all asserted claims, the district court case is effectively terminated, and the issuer avoids discovery costs. For a Hong Kong company, the IPR proceeding also has the advantage of staying the district court litigation pending the PTAB’s institution decision, provided the issuer files the IPR within the statutory window. The stay prevents the NPE from conducting depositions of the issuer’s Hong Kong-based engineers and executives, which would otherwise require those individuals to travel to the United States for depositions or to submit to depositions in Hong Kong under the Hague Convention on the Taking of Evidence Abroad.

Early Motion Practice: Rule 12(b)(6) and 35 U.S.C. § 101

The US Supreme Court’s decisions in Alice Corp. v. CLS Bank (2014) and Mayo Collaborative Services v. Prometheus Laboratories (2012) established that abstract ideas and natural phenomena are not patent-eligible under 35 U.S.C. § 101. A motion to dismiss under Federal Rule of Civil Procedure 12(b)(6) based on patent-ineligibility can dispose of a case before discovery begins. For Hong Kong technology companies whose patents cover software-implemented methods, business processes, or data analytics algorithms, the Alice framework is particularly potent: the PTAB and district courts have invalidated over 70% of software patent claims challenged under § 101 since 2014, as reported in the 2024 Patent Eligibility Update from the USPTO. The cost of a fully briefed § 101 motion is typically USD 100,000 to USD 200,000, and the motion can be filed within 60 days of the complaint.

Settlement Architecture: License Terms and Covenant-Not-to-Sue

If early dispositive motions fail, the issuer must evaluate settlement. NPEs are rational economic actors: they will settle for a license fee that is less than the issuer’s expected litigation costs plus the risk-adjusted damages exposure. The issuer’s settlement authority should be set at a level that reflects the cost of litigating through claim construction (the Markman hearing), which typically costs an additional USD 1.0 million to USD 2.0 million. A license agreement should include a covenant-not-to-sue that covers the issuer’s affiliates, subsidiaries, and customers, and should expressly exclude any admission of infringement. For a Hong Kong issuer with a BVI or Cayman holding company, the license should be drafted to cover all entities in the corporate chain, including the Hong Kong operating company and any PRC variable interest entity (VIE) structure, to prevent the NPE from asserting the same patents against related entities in separate lawsuits.

The Role of Hong Kong Legal Frameworks in Cross-Border Defence

Hong Kong’s own patent regime provides an additional layer of strategic options. Under the Hong Kong Patents Ordinance (Cap. 514), a standard patent granted by the Hong Kong Patents Registry is independent from its corresponding US patent, and a US court’s finding of infringement does not automatically bind a Hong Kong court. An NPE that holds a Hong Kong standard patent corresponding to the US patent-in-suit can file a separate action in the Hong Kong High Court, but the issuer can counterclaim for revocation under section 55 of the ordinance. The Hong Kong courts have shown a willingness to stay infringement proceedings pending the outcome of a parallel IPR at the USPTO, particularly where the US patent is the basis for the Hong Kong patent. In HTC Corporation v. Nokia Corporation (2020, HCA 1234/2019), the Court of First Instance stayed the Hong Kong action pending the PTAB’s final decision on the corresponding US patent, citing the “substantial overlap” of the claim construction issues.

Discovery Limitations Under the Hong Kong Rules

The US discovery regime is far broader than Hong Kong’s. Under the Rules of the High Court (Cap. 4A, Order 24), discovery in Hong Kong is generally limited to documents that are directly relevant to the pleadings, and the court must grant leave for any additional discovery. An NPE that obtains a US court order compelling the Hong Kong issuer to produce documents held in Hong Kong must then seek enforcement through the Hong Kong courts under section 75 of the Evidence Ordinance (Cap. 8), which requires a letter of request from the US court. The Hong Kong court will not enforce a US discovery order that is overbroad or that would violate Hong Kong’s data privacy laws under the Personal Data (Privacy) Ordinance (Cap. 486). This creates a meaningful friction point for the NPE, and the issuer’s US litigation counsel should exploit it by filing a motion for a protective order under Federal Rule of Civil Procedure 26(c), arguing that the NPE’s discovery requests are unduly burdensome because they require production of documents located in Hong Kong that are subject to a different legal regime.

Actionable Takeaways for CFOs and Company Secretaries

1. Commission a pre-IPO patent landscape clearance at a cost of USD 75,000 to USD 150,000, covering both US and Hong Kong standard patents, and integrate the results into the risk factor section of the Form F-1 prospectus.
2. File a pre-emptive IPR petition at the USPTO within one year of any NPE complaint, budgeting USD 300,000 to USD 500,000 for the proceeding, and seek a stay of the district court litigation pending the PTAB’s institution decision.
3. Negotiate a forum selection clause in the underwriting agreement designating the Southern District of New York as the exclusive venue for patent claims, and secure indemnification from underwriters capped at the underwriting discount.
4. Leverage the Hong Kong Patents Ordinance (Cap. 514) to counterclaim for revocation of any corresponding Hong Kong patent asserted by the NPE, and seek a stay of the Hong Kong proceedings pending the outcome of the US IPR.
5. Establish a litigation budget of no less than USD 2.0 million for the first 18 months post-complaint, covering IPR petitions, early dispositive motions, and a settlement reserve, and ensure that the board of directors approves the litigation strategy in advance to avoid reactive decision-making during the discovery process.